# OnCo record skl35501 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/skl35501/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "skl35501" ;
  schema:name "SKL35501"@en ;
  schema:alternateName "FL-091"@en, "225Ac-SKL35500"@en ;
  schema:description "SKL35501 is an experimental radioactive medicine from SK Life Science that seeks out tumour cells carrying the NTSR1 receptor and irradiates them from close range. It is in a first trial in people, and the FDA has given it orphan drug status for pancreatic cancer."@en ;
  schema:url <https://onco.cc/drugs/skl35501/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.sklifescienceinc.com/innovation/>, <https://clinicaltrials.gov/study/NCT07812805>, <https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1146826> ;
  onco:status "phase-1" ;
  onco:tag "pipeline", "orphan-designation" ;
  onco:modality "Actinium-225 radioligand (targeted alpha therapy)" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/> ;
  onco:technologies <https://onco.cc/technologies/targeted-alpha-therapy/> ;
  onco:companies <https://onco.cc/companies/sk-life-science/> .